NASDAQ:NBIX - Neurocrine Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$122.64 +1.59 (+1.31 %)
(As of 09/26/2018 02:35 AM ET)
Previous Close$121.05
Today's Range$120.89 - $124.38
52-Week Range$56.83 - $126.98
Volume1.19 million shs
Average Volume765,716 shs
Market Capitalization$10.82 billion
P/E Ratio-75.04
Dividend YieldN/A
Neurocrine Biosciences logoNeurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic


Debt-to-Equity Ratio1.00
Current Ratio9.19
Quick Ratio9.19


Trailing P/E Ratio-75.04
Forward P/E Ratio817.60
P/E Growth37.08

Sales & Book Value

Annual Sales$161.63 million
Price / Sales68.65
Cash FlowN/A
Price / CashN/A
Book Value$4.21 per share
Price / Book29.13


EPS (Most Recent Fiscal Year)($1.62)
Net Income$-142,540,000.00
Net Margins-16.07%
Return on Equity-14.22%
Return on Assets-6.42%


Outstanding Shares90,470,000
Market Cap$10.82 billion

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its quarterly earnings results on Tuesday, July, 31st. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.11. The business earned $96.90 million during the quarter, compared to analysts' expectations of $84.11 million. Neurocrine Biosciences had a negative return on equity of 14.22% and a negative net margin of 16.07%. The business's quarterly revenue was up 1428.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.68) earnings per share. View Neurocrine Biosciences' Earnings History.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for Neurocrine Biosciences.

What price target have analysts set for NBIX?

18 analysts have issued 1-year target prices for Neurocrine Biosciences' shares. Their forecasts range from $79.00 to $162.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $122.1111 in the next twelve months. This suggests that the stock has a possible downside of 0.4%. View Analyst Price Targets for Neurocrine Biosciences.

What is the consensus analysts' recommendation for Neurocrine Biosciences?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 18 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

What are Wall Street analysts saying about Neurocrine Biosciences stock?

Here are some recent quotes from research analysts about Neurocrine Biosciences stock:
  • 1. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and 12-month PT of $150 on NBIX. On Tuesday, we hosted a call with a physician who has deep expertise in movement disorders and is familiar with, arguably pioneered, the use of VMAT2 inhibitors in various hyperkinetic disorders, having treated thousands of pediatric Tourette Syndrome (pTS) patients. Our discussion focused on the KOL’s views on the current TS treatment landscape, unmet needs, and efficacy of VMAT2i’s. Although some investors may be skeptical of valbenazine efficacy in pTS after 2 prior study failures (one in adult and another in pTS), we are optimistic about PoS of the ongoing pTS trial. Based, in part, on our recent KOL diligence including this call, we have increased conviction in not only the probability of T-Force GOLD success, but also in the market opportunity for valbe’ in TS." (9/14/2018)
  • 2. Needham & Company LLC analysts commented, "Mesoblast announced good news that remestemcel-L (MSC-100-IV) met the primary endpoint in a Phase III trial to treat steroid-refractory acute graft- versus-host disease (GvHD)." (2/22/2018)

Who are some of Neurocrine Biosciences' key competitors?

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:
  • Kevin Charles Gorman, Chief Executive Officer & Director
  • Matthew C. Abernethy, Chief Financial Officer
  • Dimitri E. Grigoriadis, Chief Research Officer
  • Bill Wilson, Vice President-Information Technology & Operations
  • Eiry W. Roberts, Chief Medical Officer

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (14.87%), Janus Henderson Group PLC (8.20%), BB Biotech AG (3.67%), Artisan Partners Limited Partnership (2.08%), First Trust Advisors LP (1.09%) and OppenheimerFunds Inc. (0.94%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Stephen A Sherwin, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

Which major investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Frontier Capital Management Co. LLC, Millennium Management LLC, Artisan Partners Limited Partnership, BB Biotech AG, Federated Investors Inc. PA, Janus Henderson Group PLC and Northern Trust Corp. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eric Benevich, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Stephen A Sherwin and William H Rastetter. View Insider Buying and Selling for Neurocrine Biosciences.

Which major investors are buying Neurocrine Biosciences stock?

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Braun Stacey Associates Inc., Mainstay Capital Management LLC ADV, Boston Advisors LLC, American Century Companies Inc., PointState Capital LP, Macquarie Group Ltd., Orbimed Advisors LLC and FMR LLC. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $122.64.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $10.82 billion and generates $161.63 million in revenue each year. The company earns $-142,540,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Neurocrine Biosciences employs 400 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]

MarketBeat Community Rating for Neurocrine Biosciences (NASDAQ NBIX)

Community Ranking:  4.1 out of 5 (star star star star)
Outperform Votes:  703 (Vote Outperform)
Underperform Votes:  163 (Vote Underperform)
Total Votes:  866
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe NBIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBIX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/26/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel